More commonly, anti-VEGF treatments are used in the setting of metastatic disease as part of combination chemotherapy, so it can be difficult to extrapolate on the effectiveness of ctDNA as a monitoring tool for the effectiveness of anti-VEGF treatments, but the studies using targeted treatment (monoclonal antibodies or with small molecular kinase inhibitors) are described below. This evidence concerns the gene VEGFA and metastatic neoplasm.